Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Asthma

Asthma

Part of Lung Diseases, Obstructive

Subtypes of Asthma

Acute exacerbation of bronchial asthma 1 Cough variant asthma 1 Difficult-to-Control Asthma 1 Viral Asthma Exacerbations 1 Psychological stress-induced asthma 0

109 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Asthma

793 trials tracked for Asthma: 333 in phase 3 or 4 and 115 with published results. The most-cited published study has 15715 citations.

793Trials tracked
333Phase 3 & 4
0Recruiting
115With published results
Phase distribution
Phase 4 108 Phase 3 225 Phase 2 191 Phase 1 50 Other / NA 219
  1. Phase 3 Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma Completed · 15,715 cited
  2. Phase 3 Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest) Completed · 1,951 cited
  3. Phase 3 Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma Completed · 1,168 cited
  4. Phase 3 Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy Completed · 1,046 cited
  5. Phase 3 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma. Completed · 643 cited
  6. Phase 3 A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma Completed · 521 cited
Show 44 more trials
  1. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Completed · 427 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Completed · 384 cited
  3. Phase 3 A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA Completed · 314 cited
  4. Phase 3 MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects Completed · 300 cited
  5. Phase 3 Individualized Therapy For Asthma in Toddlers Completed · 296 cited
  6. Phase 3 Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids. Completed · 265 cited
  7. Phase 3 TRIple in Asthma hiGh strenGth vErsus Ics/Laba hs and tiotRopium (TRIGGER) Completed · 207 cited
  8. Phase 3 A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma. Completed · 177 cited
  9. Phase 3 Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma Completed · 174 cited
  10. Phase 3 Study on Foster Efficacy Maintenance and Reliever vs Foster Maintenance + Salbutamol Reliever in Asthmatics (MART2) Completed · 172 cited
  11. Phase 3 A Phase 3a, Repeat Dose, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Completed · 166 cited
  12. Phase 3 Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With Asthma Completed · 157 cited
  13. Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma Completed · 146 cited
  14. Phase 3 Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma Completed · 146 cited
  15. Phase 4 A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab Completed · 143 cited
  16. Phase 3 Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations Completed · 143 cited
  17. Phase 3 Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma Completed · 141 cited
  18. Phase 3 Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist Completed · 141 cited
  19. Phase 4 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old Completed · 137 cited
  20. Phase 3 Placebo-controlled Efficacy and Safety Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Completed · 127 cited
  21. Phase 3 A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype Completed · 126 cited
  22. Phase 3 A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma Completed · 125 cited
  23. Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma Completed · 124 cited
  24. Phase 3 Steroids In Eosinophil Negative Asthma Completed · 122 cited
  25. Phase 3 Cessation Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients Completed · 119 cited
  26. Phase 3 An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma Completed · 116 cited
  27. Phase 3 A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents Completed · 109 cited
  28. Phase 3 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Completed · 98 cited
  29. Phase 3 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. Completed · 98 cited
  30. Phase 3 The Safety and Efficacy of Intralymphatic Immunotherapy in Pollen Allergic Adolescents and Young Adults With Asthma Completed · 92 cited
  31. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Completed · 88 cited
  32. Phase 3 A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Completed · 88 cited
  33. Phase 3 Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils Completed · 84 cited
  34. Phase 3 An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils Completed · 84 cited
  35. Phase 3 Acetaminophen Versus Ibuprofen in Children With Asthma Completed · 80 cited
  36. Phase 4 Long-acting Beta Agonist Step Down Study Completed · 70 cited
  37. Phase 4 The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma Completed · 70 cited
  38. Phase 3 AZMATICS: AZithroMycin/Asthma Trial In Community Settings Completed · 69 cited
  39. Phase 4 Use of Mobile Devices and the Internet to Streamline an Asthma Clinical Trial Completed · 67 cited
  40. Phase 3 Best African American Response to Asthma Drugs Completed · 67 cited
  41. Phase 4 A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects Completed · 65 cited
  42. Phase 3 Blacks and Exacerbations on Long Acting Beta Agonists (LABA) vs. Tiotropium (BELT) Completed · 64 cited
  43. Phase 3 Asthma Action at Erie Trial Completed · 61 cited
  44. Phase 3 Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control Completed · 56 cited

Showing the 50 most-cited and recently-updated of 793 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Asthma: what the trials found

Several phase 3 trials demonstrate that inhaled corticosteroid (ICS)/long-acting beta-agonist (LABA) combinations improve lung function and reduce exacerbations in asthma. CHF 5993 (200/6/12.5 µg) significantly improved pre-dose FEV1 at week 26 (p=0.003) and peak FEV1 (p<0.001) versus comparators, though exacerbation rate reduction was not significant (p=0.110) 2. CHF1535 (200/6 µg pMDI) significantly improved morning and evening peak expiratory flow (PEF) over the treatment period (p<0.001) 5. BFF MDI 320/9.6 µg improved morning pre-dose trough FEV1 at week 24 (p=0.0447) and reduced rescue medication use (p=0.0146) 7; BFF MDI 160/9.6 µg similarly improved trough FEV1 at week 12 (p=0.0096) and reduced rescue medication use (p=0.0058) 8. Salbutamol alone reduced severe exacerbations (p<0.001) and systemic corticosteroid courses (p<0.001) 3. A quality improvement (QIP) intervention increased the proportion of patients on ICS-based maintenance/reliever treatment (p<0.0001) and improved ACQ-5 scores 1. Ipratropium bromide improved FEV1 percent change post-ipratropium (p=0.032) 20.

Depemokimab (GSK3511294) did not significantly reduce clinically significant exacerbations over 52 weeks (p=0.079) 4 and showed no significant improvements in ACQ-5 or SGRQ scores 410. Beclomethasone dipropionate/formoterol fumarate (Inhaler A) did not significantly change VAS perceptions of asthma (p=0.385) 6. PT027 showed non-inferiority but not superiority in FEV1 change post-mannitol challenge (p=0.303) 9.

Recent results — preliminary, needs further review

  • CHF 5259 (12.5 µg) plus Qvar significantly improved peak FEV1 on day 42 (p<0.001) 12. CHF 5259 plus Foster 100/6 µg also improved peak FEV1 on day 42 (p<0.001), but pre-dose FEV1 changes were not significant (p=0.168 and p=0.484) 13.
  • MCT (Methacholine challenge test) showed no significant effect on FEV1 percent predicted (p=0.447) or ACQ-6 (p=0.232), but CompEx events per year were significant (p=0.014) 14.
  • Amlitelimab did not significantly reduce severe asthma exacerbation rate (p=0.3626), improve FEV1 (p=0.3615), or ACQ-5 (p=0.1579) over 48 weeks 15.
  • Hyperpolarized 129XeMRI showed no significant changes in peripheral blood neutrophils (p=0.53) or eosinophils (p=0.76) 16.
  • Triamcinolone acetonide showed a change in ACQ score of 0.52 17. Depemokimab in a phase 1 trial showed complement C3 and C4 ratios near baseline 18. GSNO challenge altered FeNO and FEV1 (p<0.1) 19. HFA-152a showed similar radiolabeled particle retention over time 21. Salbutamol HFA-152a is under investigation 22.

For the clinician treating this condition

  • ICS/LABA combinations (e.g., CHF 5993, CHF1535, BFF MDI) improve lung function and reduce rescue medication use; however, exacerbation reduction may not always reach significance.
  • Salbutamol alone reduces severe exacerbations and systemic corticosteroid use.
  • Depemokimab and amlitelimab did not show significant benefits in key outcomes in these trials.

AI synthesis of 21 cited trials, updated Jun 20, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Chlorinated pool air exposure is linked to mucosal irritation and asthma-like symptoms in swimmers
Orthopedics & Sports Medicine Sys. Review
Chlorinated pool air exposure is linked to mucosal irritation and asthma-like symptoms in swimmers Chlorinated pool air may cause asthma like symptoms in swimmers
This mini review synthesizes evidence regarding the impact of chlorinated pool air on competitive swimmers and workers. The authors conclude…
Swimming in chlorinated pools can lead to lung irritation and inflammation, posing a risk for athletes with sensitive airways.
Frontiers Jul 29, 2026
Maternal hypertensive disorders of pregnancy are associated with increased offspring asthma risk
Psychiatry Meta-analysis
Maternal hypertensive disorders of pregnancy are associated with increased offspring asthma risk Maternal Pregnancy High Blood Pressure Linked to Higher Asthma Risk
This meta-analysis of over three million mother-infant pairs found a significant association between maternal hypertensive disorders of preg…
New data suggests that mothers with high blood pressure during pregnancy may have children at a higher risk for developing asthma.
Frontiers Jul 29, 2026
CXCL16/CXCR6 axis exerts bidirectional regulatory influence on neoplasms and inflammatory disorders like asthma
Oncology Sys. Review
CXCL16/CXCR6 axis exerts bidirectional regulatory influence on neoplasms and inflammatory disorders like asthma New Biological Pathways May Help Doctors Treat Cancer and Asthma Better
This narrative review examines the CXCL16/CXCR6 axis as a multifaceted regulator in various pathological processes, including neoplasms and …
Scientists are looking at how a specific protein pathway can influence both cancer growth and lung inflammation.
Frontiers Jul 23, 2026
Predictors of Polysomnography Progression in Children with Mild Sleep-Disordered Breathing
Pediatrics RCT
Predictors of Polysomnography Progression in Children with Mild Sleep-Disordered Breathing Certain risk factors may signal when children need surgery sooner
Identifying specific risk factors like ADHD and asthma can help clinicians determine which children with mild sleep-disordered breathing req…
New data shows that conditions like asthma and ADHD can make it more likely that a child's snoring and breathing issues will worsen over tim…
Jul 18, 2026
Upstream alarmins IL-33 and TSLP emerge as key targets in T2 asthma pathogenesis
Allergy & Immunology Sys. Review
Upstream alarmins IL-33 and TSLP emerge as key targets in T2 asthma pathogenesis New research identifies key triggers behind Type 2 asthma inflammation
This systematic review synthesizes the complex immune network underlying T2 asthma, highlighting epithelial-derived alarmins IL-33 and TSLP …
Scientists have identified specific early signals that trigger the complex immune response in people with Type 2 asthma.
Frontiers Jul 17, 2026
Health literacy is moderately associated with improved self-care behaviors in patients with multiple chronic diseases
Primary Care & Family Medicine Meta-analysis
Health literacy is moderately associated with improved self-care behaviors in patients with multiple chronic diseases Better health literacy helps people manage chronic diseases more effectively
This meta-analysis of 138 studies found a moderate positive association (r = 0.29, 95% CI: 0.26-0.31) between health literacy and self-care …
Understanding medical information and using digital tools can help people with chronic conditions like diabetes or heart failure manage thei…
Jul 7, 2026
Genetic variant identification improves polygenic risk prediction for patients with asthma
Allergy & Immunology Meta-analysis
Genetic variant identification improves polygenic risk prediction for patients with asthma New Genetic Mapping Improves Prediction of Asthma Risk
Researchers investigated genetic variants associated with asthma in a large cohort of individuals of European ancestry. The analysis identif…
Researchers used deep learning to identify 69 new genetic markers for asthma, improving how doctors can predict risk in people of European a…
Jul 4, 2026
Over one-third of workers with occupational asthma experience adverse occupational outcomes
Allergy & Immunology Meta-analysis
Over one-third of workers with occupational asthma experience adverse occupational outcomes Over One-Third of Workers with Occupational Asthma Face Job Hardships
This meta-analysis of 3,393 adults with occupational asthma found a pooled prevalence of 35.9% for adverse occupational outcomes (AOO). Sign…
More than one-third of workers with occupational asthma face serious job impacts like unemployment or disability, highlighting the need for …
Jul 1, 2026
PEFR-guided therapy shows no difference in symptom control compared to symptom-guided therapy in acute asthma
Allergy & Immunology RCT
PEFR-guided therapy shows no difference in symptom control compared to symptom-guided therapy in acute asthma Trial shows PEFR values do not change asthma treatment outcomes
This pilot randomized controlled trial of 210 patients with acute asthma found no significant difference in symptom control at 150 minutes b…
A pilot study found that using peak flow measurements does not improve symptom control or hospital rates for patients with acute asthma in e…
Jul 1, 2026
BiPAP improves oxygenation over HFNC in pediatric asthma exacerbation, but evidence is limited
Allergy & Immunology Meta-analysis
BiPAP improves oxygenation over HFNC in pediatric asthma exacerbation, but evidence is limited BiPAP may offer better oxygen levels for children with asthma
This meta-analysis of 374 children aged 2-18 with asthma exacerbation found no significant difference between high-flow nasal cannula (HFNC)…
New data suggests BiPAP provides better oxygenation than nasal cannulas for children during asthma attacks, though both methods provide adeq…
Jul 1, 2026
Bidirectional associations exist between obstructive lung diseases and inflammatory bowel disease across 30 observational studies
Allergy & Immunology Meta-analysis
Bidirectional associations exist between obstructive lung diseases and inflammatory bowel disease across 30 observational studies Lung Disease and Inflammatory Bowel Disease Show Linked Risks
This meta-analysis of 30 observational studies identifies bidirectional associations between obstructive lung diseases (COPD, asthma, bronch…
Research shows a link between inflammatory bowel disease and several lung conditions, including asthma and COPD, suggesting these issues oft…
Frontiers Jun 30, 2026
Routine serum lipid profiles may serve as markers for systemic metabolism in allergic diseases
Allergy & Immunology Sys. Review
Routine serum lipid profiles may serve as markers for systemic metabolism in allergic diseases Blood fat levels may offer clues about asthma severity
This mini review examines the clinical associations of routine serum lipid measures in patients with asthma, atopic dermatitis, and allergic…
New research suggests that routine blood tests for fats like cholesterol could help doctors better understand and categorize different types…
Frontiers Jun 29, 2026

Questions about Asthma

Can high ferritin levels predict acute asthma attacks in children?

High ferritin levels are linked to a higher risk of acute asthma attacks in children, but vitamin D levels do not show a clear benefit for lung function.

Full answer →
What early-life exposures might increase the risk of childhood asthma?

Early-life exposures linked to higher childhood asthma risk include antibiotics, phthalates, prenatal cleaning products, tobacco smoke, air pollution, preterm birth, rapid weight gain, and gut/airway microbiome changes.

Full answer →
What clinical remission definition do experts suggest for severe asthma?

Experts suggest clinical remission in severe asthma means no exacerbations, no oral corticosteroids, good symptom control, and stable or optimal lung function.

Full answer →
Does biologic therapy improve asthma control for patients with severe asthma?

Yes, biologic therapy significantly improves asthma control for patients with severe asthma, reducing exacerbations and improving symptoms and lung function.

Full answer →
What are the lung function goals for patients with severe asthma?

Lung function goals for severe asthma focus on achieving optimal individual FEV1 and maintaining stability, rather than normal values, as part of clinical remission.

Full answer →
Is tezepelumab a treatment option for severe asthma patients with low inflammation?

Yes, tezepelumab is approved for severe asthma regardless of inflammation type, including low type 2 inflammation, though benefit may be smaller in these patients.

Full answer →
Can switching asthma biologics help reduce severe asthma attacks?

Switching asthma biologics often reduces severe asthma attacks, improves lung function, and lowers the need for oral steroids, though the specific benefit depends on a patient's inflammation type.

Full answer →
Does nurse-led rehabilitation consultation help improve my asthma control in primary care?

Yes, a 2023 trial found that a nurse-led structured rehabilitation consultation significantly improved asthma control, quality of life, and patient enablement in primary care compared to usual nursing care.

Full answer →
See all 10 questions about Asthma →

All Asthma Articles